Lacer SA

Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of the global rights to Intrarosa® from Endoceutics, Inc., a subsidiary of Endorecherche, Inc. The transaction includes 108 issued and pending patents across the globe with the latest expiring in 2033 including 3 Orange Book listed patents. Intrarosa® is currently available in almost all major markets, including the US, UK, EU, Canada, and Israel through our local partners like, Theramex, Tecnimede, Avia, Lupin (BSE: 500257), Dexcel, Labatec, Lacer, Lee’s Pharma, and Valenta; with Asian market launches in 2025. This press release features multimedia. View the full release here: Intrarosa (Photo: Business Wire) Apurva Saraf, President and CEO of Cosette stated, “This transformative acquisition further strengthens Cosette’s commitment to women’s health with a patent protected, novel drug formulation. In partnership with MSH Pharma Inc., Cosette will leverage its unique commercial and manufacturing capabilities to ensure continued patient access to Intrarosa®. We look forward to expanding Cosette’s global footprint in new territories and with our existing distribution partners.” Intrarosa® is the only prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia (a common symptom of vulvar and vaginal atrophy (VVA) due to menopause). Unlike conventional pharmacological estrogen-containing medications, the unique label of Intrarosa® differentiates it from all other hormone replacement therapies on the market today in that it does not carry a boxed safety warning on its label. There are an estimated 64 million post-menopausal women, and as many as 32 million of those women suffer from VVA symptoms just in the U.S. alone. Studies suggest that between 44 percent and 78 percent of women with VVA suffer from dyspareunia. About Cosette Pharmaceuticals, Inc.: Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. Cosette has a fast-growing portfolio of branded pharmaceuticals consisting of products in women’s health, cardiology and migraine indications. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories, which has led to consistent supply to customers and commercialization success. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by more than 350+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. Follow us on LinkedIn.

Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros. Thanks to Lacer's 5 leading brands in Spain, Italfarmaco will become the most important player in Spain’s health and personal hygiene sectors This merger represents an excellent opportunity for Italfarmaco's growth both in Spain and internationally MILAN--(BUSINESS WIRE)-- Italfarmaco, an Italian multinational company in the chemical-pharmaceutical sector, has acquired 100% of Lacer Pharmaceuticals, one of the leading companies in Spain in the area of health and personal hygiene. With an experience of over 70 years, a turnover in 2021 of over 150 million euros and almost 500 employees, Lacer is the market leader in practically all the areas in which it operates, in particular in the oral and dental sector with the Lacer brand, and brands such as Thrombocid, Pilexil, Anso and Talquistina. Lacer also has a broad portfolio of drugs in the cardiovascular and urogynecological sectors. With this acquisition, Italfarmaco is strengthening its presence in the Spanish healthcare market, where it is already present with established brands, and is consolidating its current business areas in which it has been successfully operating for over 30 years in Italy and around the world. These include the thrombosis and critical ischemia sector, with brands such as Ghemaxan; gynecology with Natalben, Nuperal / Cariban and Ainara; and neurology and psychiatry sectors with brands such as Sonirem and Gliatilin. The Company recently achieved a major breakthrough with Givinostat, the first product that has been shown to be clinically significant in a Phase 3 study of patients with Duchenne muscular dystrophy (DMD), for which registration in the United States and Europe will be requested in the following months. Furthermore, Italfarmaco, by incorporating the Lacer production plant in Cerdanyola del Valles, will add an important asset to the industrial activities of the Group which already has 5 production plants. The integration into Italfarmaco will allow Lacer to consolidate its leading position in Spain, actively investing in existing brands and expanding its product portfolio, both in the healthcare sector and in the Prescription Medicines division. Furthermore, Lacer, benefiting from Italfarmaco's global sales network of branches and distributors, will be able to increase its growth internationally. Francesco De Santis, President of Italfarmaco, comments: “This acquisition represents a strong consolidation of our company in the Spanish market and represents a further impetus for our growth at international level. Lacer's business, brands and our pool of talented people represent a strong element of continuity to Italfarmaco's spirit of growth both in the areas where we are already present and in new therapeutic alternatives that can improve people's health." Lacer comments: "Lacer will benefit from the support of a new experienced partner that will allow both companies to grow towards the creation of a European pharmaceutical leader. This integration will allow Lacer to continue its success story and ensure the continuation of its legacy that started over 70 years ago.” Italfarmaco ITALFARMACO is an Italian multinational based in Milan that operates in Italy and abroad in the pharmaceutical and chemical-pharmaceutical sector, with products with a high therapeutic content which mainly fall into the cardiovascular, immuno-oncological and gynecological areas. With over 80 years of history (it was founded in 1938), Italfarmaco is directly present in 30 countries, with 5 production sites and more than 3300 employees (at Group level). The company has modern and sophisticated industrial plants where it produces medicinal specialties in pre-filled syringes, sterile preparations for injection, oral, solid and liquid products. The mission of the company, within the scope of business logic and fair competition, is to contribute to the improvement of quality and the prolongation of human life through the creation of pharmaceutical products and services relating to pathologies with the greatest impact on personal health, such as immuno-oncological, haemato-oncological, and rare diseases. Much of its pipeline is the result of internal research and development, including the Givinostat project, the first product to be clinically significant in a Phase 3 study in patients with Duchenne muscular dystrophy (DMD), for which registration in the United States and Europe will be requested in the coming months. Lacer LACER is a pharmaceutical company founded in 1949 in Barcelona that operates through two segments: personal care and prescription drugs. The company, with over 70 years of history, is a leader in the pharmacy channel, specializing in segments such as oral hygiene, the treatment of varicose veins and hair loss. Owner of well-known brands such as Lacer, Thrombocid, Pilexil, Talquistina and Anso, Lacer has an annual turnover of over 150 million euros, employs 476 people, and is present in 18 countries. View source version on businesswire.com: Contacts For more information Veronica Carminati – v.carminati@italfarmacogroup.com Cell. 351 7623422 - Tel. 02.6443.3502 Source: Italfarmaco View this news release online at:

Italfarmaco acquires 100% of Lacer, a Spanish pharmaceutical company that is a leader in health care and personal hygiene Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros. Thanks to Lacer's 5 leading brands in Spain, Italfarmaco will become the most important player in Spain’s health and personal hygiene sector s This merger represent s an excellent opportunity for Italfarmaco's growth both in Spain and internationally Milan, 24 July 2022 - Italfarmaco, an Italian multinational company in the chemical -pharmaceutical sector, has acquired 100% of Lacer Pharmaceuticals, one of the leading companies in Spain in the area of health and personal hygiene. With an experience of over 70 years, a turnover in 2021 of over 150 million euros and almost 500 employees, Lacer is the market leader in practically all the areas in which it operates, in particular in the oral and dental sector with the Lacer brand , and brands such as Thrombocid, Pilexil, Anso and Talquistina. Lacer also has a broad portfolio of drugs in the cardiovascular and urogynecological sectors. With this a cquisition, Italfarmaco is strengthening its presence in the Spanish healthcare market , where it is already present with established brands, and is consolidating its current business areas in which it has been successfully operating for over 30 years in It aly and around the world. These include the thrombosis and critical ischemia sector , with brands such as Ghemaxan; gynecology with Natalben , Nuperal / Cariban and Ainara; and neurology and psychiatry sectors with brands such as Sonirem and Gliatilin. The C ompany recently achieved a major breakthrough with Givinostat, the first product that has been shown to be clinically significant in a Phase 3 study of patients with Duchenne muscular dystrophy (DMD), for which registration in the United States and Europe will be requested in the following months. Furthermore, Italfarmaco, by incorporating the Lacer production plant in Cerdanyola del Valles, will add an important asset to the industrial activities of the Group which already has 5 production plants. The in tegration into Italfarmaco will allow Lacer to consolidate its leading position in Spain, actively investing in existing brands and expanding its product portfolio, both in the healthcare sector and in the Prescription Medicines division. Furthermore, Lace r, benefiting from Italfarmaco's global sales network of branches and distributors, will be able to increase its growth internationally. Francesco De Santis, President of Italfarmaco , comments : “This acquisition represents a strong consolidation of our com pany in the Spanish market and represents a further impetus for our growth at international level. Lacer's business, brands and our pool of talented people represent a strong element of continuity to Italfarmaco's spirit of growth both in the areas where w e are already present and in new therapeutic alternatives that can improve people's health ”. Lacer comments: " Lacer will benefit from the support of a new experienced partner that will allow both companies to grow towards the creation of a European phar maceutical leader. This integration will allow Lacer to continue its success story and ensure that the legacy that started over 70 years ago will continue ”. Italfarmaco ITALFARMACO is an Italian multinational based in Milan that oper ates in Italy and abroad in the pharmaceuti cal and chemical -pharmaceutical sector, with products with a high therapeutic content which mainly fall into the cardiovascular, immuno -oncological and gynecological areas. With over 80 years of history (it was fo unded in 1938), Italfarmaco is directly pre sent in 30 countries, with 5 production sites and more than 3300 employees (at Group level). The company has modern and sophisticated industrial pla nts where it produces medicinal specialties in pre -filled syringe s, sterile preparations for injection, oral, solid and liquid products. The mission of the company, within the scope of business lo gic and fair competition, is to contribute to the improvement of quality and the prolongation of human life through the creat io n of pharmaceutical products and services relating to pathologies with the greatest impact on personal health, such as immuno -oncological, haemato -oncological, and rare diseases. Much of its pipeline is the result of internal research and development, including the Givinostat project, the first product to be clinically significant in a Phase 3 study in patients with Duchenne muscular dystrophy (DMD), for which registration in the U nited States and Europe will be requ ested in the coming months. Lacer LACER is a pharmaceutical company founded in 1949 in Barcelona that operates through two segments : personal care and prescription drugs. The company, with over 70 years of history, is a leader in the pharmacy channel, specializing in segments such as oral hygiene, the treatment of varicose veins and hair loss. Owner of well -known brands such as Lacer, Thrombocid, Pilexil, Talquistina and Anso, Lacer has an annual turnover of over 150 million euros, employs 476 people , and is present in 18 countries.